UC San Diego's Moores Cancer Center has received a $1 million donation from pharmaceutical giant Pfizer to support early ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

Funding will support Moores Cancer Center’s efforts to develop a unique, large-scale program to drive early detection and ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...